Abstract:IgA nephropathy (IgAN) is the most common primary glomerulonephritis, frequently leading to end-stage renal disease, as there is no disease-specific therapy. IgAN is diagnosed from pathological assessment of a renal biopsy specimen based on predominant or codominant IgA-containing immunodeposits, usually with complement C3 co-deposits and with variable presence of IgG and/or IgM. The IgA in these renal deposits is galactose-deficient IgA1, with less than a full complement of galactose residues on the O-glycans in the hinge region of the heavy chains. Research from the past decade led to the definition of IgAN as an autoimmune disease with a multi-hit pathogenetic process with contributing genetic and environmental components. In this process, circulating galactose-deficient IgA1 (autoantigen) is bound by antiglycan IgG or IgA (autoantibodies) to form immune complexes. Some of these circulating complexes deposit in glomeruli, and thereby activate mesangial cells and induce renal injury through cellular proliferation and overproduction of extracellular matrix components and cytokines/chemokines. Glycosylation pathways associated with production of the autoantigen and the unique characteristics of the corresponding autoantibodies in patients with IgAN have been uncovered. Complement likely plays a significant role in the formation and the nephritogenic activities of these complexes. Complement activation is mediated through the alternative and lectin pathways and probably occurs systemically on IgA1-containing circulating immune complexes as well as locally in glomeruli. Incidence of IgAN varies greatly by geographical location; the disease is rare in central Africa but accounts for up to 40% of native-kidney biopsies in eastern Asia. Some of this variation may be explained by genetically determined influences on the pathogenesis of the disease. Genome-wide association studies to date have identified several loci associated with IgAN. Some of these loci are associated with the increased prevalence of IgAN, whereas others, such as deletion of complement factor H-related genes 1 and 3, are protective against the disease. Understanding the molecular mechanisms and genetic and biochemical factors involved in formation and activities of pathogenic IgA1-containing immune complexes will enable the development of future disease-specific therapies as well as identification of non-invasive disease-specific biomarkers.

Increased immunoglobulin-secreting cells in the blood of patients with active idiopathic IgA nephropathy

Progress in Pathogenesis of Immunoglobin A Nephropathy

Clinical and Pathology Features of IgA Nephropathy with Active Tubular Interstitial Lesions

Immune abnormalities in IgA nephropathy

The Level of Serum Secretory IgA of Patients with IgA Nephropathy is Elevated and Associated with Pathological Phenotypes.

The Immunohistology of IgA Nephropathy

The Level of Urinary Secretory Immunoglobulin A (siga) of Patients with IgA Nephropathy is Elevated and Associated with Pathological Phenotypes.

Increased plasma sVCAM-1 is associated with severity in IgA nephropathy

IgA-containing immune complexes in the urine of IgA nephropathy patients

The Clinicopathologic Characteristics and Complement Activation of Antineutrophil Cytoplasmic Antibody-associated Vasculitides with Glomerular IgA Deposition

The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy

Low Serum IgG4 Level: a Potential Diagnostic Biomarker for IgA Nephropathy.

Identification and characterization of circulating immune complexes in IgA nephropathy

Overactivation of the complement system may be involved in intrarenal arteriolar lesions in IgA nephropathy

[Diagnosis and Treatment of IgA Nephropathy-2023]

Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1

Immunological Pattern in IgA Nephropathy

An update on the pathogenesis and treatment of IgA nephropathy

Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy

Mast cell infiltration in the renal tissue in patients with IgA nephropathy

Endothelial Injury by Circulating IgA1 Complex Through the Activation of Mesangial Cells in IgA Nephropathy.